T
Torben Plesner
Researcher at University of Southern Denmark
Publications - 205
Citations - 11134
Torben Plesner is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Daratumumab & Multiple myeloma. The author has an hindex of 45, co-authored 186 publications receiving 9295 citations. Previous affiliations of Torben Plesner include University of Copenhagen & Finsen Laboratory.
Papers
More filters
Journal ArticleDOI
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
Hervé Avet-Loiseau,Tineke Casneuf,Christopher Chiu,Jacob P. Laubach,Je-Jung Lee,Philippe Moreau,Torben Plesner,Hareth Nahi,Nushmia Z. Khokhar,Ming Qi,Jordan M. Schecter,Victoria Carlton,Xiang Qin,Kevin Liu,Kaida Wu,Sen H. Zhuang,Tahamtan Ahmadi,A. Kate Sasser,Jesús F. San-Miguel +18 more
TL;DR: This is the first comprehensive and prospective study of MRD to date in randomized phase 3 clinical trials of RRMM patients and investigates the ability of DARA-containing regimens to drive deep responses in this challenging population.
Journal ArticleDOI
Insights on Multiple Myeloma Treatment Strategies
Maria-Victoria Mateos,Heinz Ludwig,Ali Bazarbachi,Meral Beksac,Joan Bladé,Mario Boccadoro,Michele Cavo,Michel Delforge,Meletios A. Dimopoulos,Thierry Facon,Catarina Geraldes,Hartmut Goldschmidt,Roman Hájek,Markus Hansson,Krzysztof Jamroziak,Merav Leiba,Tamás Masszi,Larisa P. Mendeleeva,Michael O'Dwyer,Torben Plesner,Jesús F. San-Miguel,Christian Straka,Niels W.C.J. van de Donk,Kwee Yong,Samo Zver,Philippe Moreau,Pieter Sonneveld +26 more
TL;DR: A group of experts met to discuss diagnostic and treatment guidelines, examine current clinical practice, and consider how new clinical trial data may be integrated into the management of multiple myeloma in the future.
Journal ArticleDOI
Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
Ajai Chari,Hareth Nahi,Maria-Victoria Mateos,Henk M. Lokhorst,Jonathan L. Kaufman,Philippe Moreau,Albert Oriol,Torben Plesner,Lotfi Benboubker,Peter Hellemans,Tara Masterson,Pamela L. Clemens,Kevin Liu,Jesús F. San-Miguel,Saad Z. Usmani +14 more
Journal ArticleDOI
HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma.
Anton Hagenbeek,Torben Plesner,Peter Johnson,Lars Pedersen,Janusz Walewski,Andrzej Hellmann,Brian K. Link,Tadeusz Robak,Marek Z. Wojtukiewicz,Michael Pfreundschuh,Michael Kneba,Andreas Engert,Pieter Sonneveld,Jørgen Petersen,John Radford +14 more
TL;DR: HuMax-CD20 as discussed by the authors targets a novel epitope of the CD20 molecule on B-cells and stops the growth of engrafted B-cell tumors in SCID mice.
Journal ArticleDOI
Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study
Shaji Kumar,Thierry Facon,Saad Z. Usmani,Torben Plesner,Robert Z. Orlowski,Cyrille Touzeau,Supratik Basu,Nizar J. Bahlis,Hartmut Goldschmidt,Michael O'Dwyer,Christopher P. Venner,Katja Weisel,Cyrille Hulin,Lionel Karlin,Meir Preis,Annemiek Broyl,William Renwick,Markus Hansson,Maria Krevvata,Jianping Wang,Rian Van Rampelbergh,Jon Ukropec,Clarissa M. Uhlar,Rachel Kobos,Aurore Perrot +24 more
TL;DR: Adding DARA to Rd continued to result in deeper responses with higher rates of ≥CR and ≥very good partial response (VGPR) and the PFS benefit of D-Rd in prespecified subgroups, including patients with high cytogenetic risk, was generally consistent with overall results.